by Mark Curtis | Jul 9, 2014
. Welcome to your Update from the Clinic for the month of June. Neuralstem presented final data on a first-in-class drug for the treatment of major depressive disorder, which is proving to be an effective and non-invasive means to boost brain volume. OncoMed has a...
by Sara M. Nolte | Jun 9, 2014
> I recently wrote about the dilemma many cancer stem cell (CSC) researchers face when trying to model their disease of interest in the lab. So assuming a researcher has successfully chosen their model – what happens next? Allow me to introduce to you some of the...
by Sara M. Nolte | Apr 8, 2014
> The thing that is so intriguing about cancer stem cells (CSCs), from a cancer researcher’s perspective, is their powerful potential as therapeutic targets. While CSCs can create or regenerate tumours (causing relapse in some patients despite our best efforts to...
by Mark Curtis | Feb 4, 2014
. Welcome to your Update from the Clinic for the month of January! We start the year off with the German health authority approving Pluristem’s next generation GMP cell manufacturing facility. Neuralstem successfully, and safely, transplants NSI-556 cells directly...
by Mark Curtis | Jan 13, 2014
. Welcome to your Regenerative Medicine Deal Review for the month of December. Toronto-based Stem Cell Therapeutics successfully executed on a financing of $33 million, while Pluristem announces it is moving forward on a licensing agreement with Korea-based CHA....
Comments